Logo
x

Search

Subscribe Now

Lebrikizumab

Lilly Reports Results of Lebrikizumab in P-III ADvocate 1 and 2 Studies for the Treatment of Moderate to Severe Atopic Dermatitis

Lilly Reports Results of Lebrikizumab in P-III ADvocate 1 and 2 Studies for the Treatment of Moderate to Severe Atopic Dermatitis

  • August 16, 2021
Eli Lilly to Acquire Dermira for $1.1B

Eli Lilly to Acquire Dermira for $1.1B

  • January 10, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.